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Abstract 26 
Aberrant epileptic activity is detectable at early disease stages in Alzheimer’s disease (AD) 27 
patients and in AD mouse models. Here, we investigated in young ArcticAβ mice whether 28 
AD-like pathology renders neuronal networks more susceptible to development of acquired 29 
epilepsy induced by unilateral intrahippocampal injection of kainic acid (IHK). In this 30 
temporal lobe epilepsy model, IHK induces a status epilepticus followed after two weeks by 31 
spontaneous recurrent seizures (SRS). ArcticAβ mice exhibited more severe status epilepticus 32 
and early onset of SRS. This hyperexcitable phenotype was characterized in CA1 neurons by 33 
decreased synaptic strength, increased kainic acid-induced LTP, and reduced frequency of 34 
spontaneous inhibitory currents. However, no difference in neurodegeneration, 35 
neuroinflammation, axonal reorganization or adult neurogenesis was observed in ArcticAβ 36 
mice compared to wildtype littermates following IHK-induced epileptogenesis. Neuropeptide 37 
Y (NPY) expression was reduced at baseline and its IHK-induced elevation in mossy fibers 38 
and granule cells was attenuated. However, although this alteration might underlie premature 39 
seizure onset, neutralization of soluble Aβ species by intracerebroventricular Aβ-specific 40 
antibody application mitigated the hyperexcitable phenotype of ArcticAβ mice and prevented 41 
early SRS onset. Therefore, development of seizures at early stages of AD is mediated 42 
primarily by Aβ species causing widespread changes in synaptic function. 43 
 44 
 45 
46 
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Introduction 47 
Alzheimer’s disease is the most prevalent age-related dementia, characterized by progressive 48 
neuronal dysfunctions. Early stages of Alzheimer’s disease and other age-related dementia 49 
are associated with aberrant network activity, including a high incidence of unprovoked 50 
epileptic seizures (Hesdorffer et al., 1996; Amatniek et al., 2006; Scarmeas et al., 2009; 51 
Vossel et al., 2013; Vossel et al., 2016). Early neurochemical alterations render neuronal 52 
networks susceptible to seizure generation (Palop & Mucke, 2016). Indeed, different mouse 53 
models of Alzheimer’s disease exhibit neuronal hyperactivity and even interictal spikes long 54 
before the occurrence of plaques (Busche et al., 2012; Kam et al., 2016). While 55 
hyperexcitability reduces seizure threshold in Alzheimer’s disease-transgenic mice (Palop et 56 
al., 2007; Roberson et al., 2007; Westmark et al., 2008; Born et al., 2014), it is unknown 57 
whether it is causally related to onset of spontaneous recurrent seizures (SRS).  58 
Alzheimer’s disease and epilepsy, in particular temporal lobe epilepsy, share major 59 
pathogenic mechanisms, including neurodegeneration, synaptic dysfunction, inflammation, 60 
and altered adult neurogenesis. In mouse models of temporal lobe epilepsy, loss of 61 
parvalbumin-, calbindin-, somatostatin- and neuropeptide Y-expressing interneurons occurs 62 
in CA1 and dentate gyrus early during epileptogenesis (Bouilleret et al., 2000a; Bouilleret et 63 
al., 2000b; Andre et al., 2001). Similarly, different mouse models of Alzheimer’s disease 64 
show reduced numbers of interneurons in these regions (Ramos et al., 2006; Mahar et al., 65 
2016); and functional impairments of parvalbumin-expressing interneurons were directly 66 
related to network hypersynchrony in parietal cortex (Verret et al., 2012). In granule cells of 67 
the dentate gyrus, calbindin expression is disease stage-dependently reduced in mouse models 68 
and patients with Alzheimer’s disease (Palop et al., 2003; Stefanits et al., 2014). Moreover, 69 
temporal lobe epilepsy is characterized by recurrent sprouting of mossy fiber collaterals 70 
(Buckmaster, 2012) and by ectopic expression of neuropeptide Y in dentate granule cells 71 
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(Marksteiner et al., 1990; Tonder et al., 1994; Vezzani et al., 1999). Transgenic Alzheimer’s 72 
disease mouse models revealed a similar adaptation to a hyperexcitable network, including 73 
mossy fiber sprouting onto GABAergic basket cells and hilar interneurons (Palop et al., 74 
2007). In both temporal lobe epilepsy and Alzheimer’s disease, activation of innate immunity 75 
is an important pathogenic feature. For instance, in temporal lobe epilepsy, secreted cytokines 76 
render the neuronal network hyperexcitable and thereby more susceptible to seizures (Viviani 77 
et al., 2003; Maroso et al., 2010; Gardoni et al., 2011). Likewise, amyloid β recruits 78 
microglia (Alzheimer et al., 1995; Meyer-Luehmann et al., 2008; Wang et al., 2015) and thus 79 
triggers inflammatory cytokine release, causing various sequelae associated with Alzheimer’s 80 
disease (Heneka et al., 2013). Finally, neurogenesis is altered in both temporal lobe epilepsy 81 
and Alzheimer’s disease. Prolonged seizure activity transiently increases precursor cell 82 
proliferation (Parent et al., 1997; Jessberger et al., 2005), followed by neurogenic niche 83 
destruction and impaired hippocampal neurogenesis (Kralic et al., 2005; Ledergerber et al., 84 
2006; Sierra et al., 2015). In Alzheimer’s disease, survival of newborn neurons is impaired in 85 
mice with plaque-burden (Verret et al., 2007), while in young Alzheimer’s disease 86 
transgenic, accelerated development of newborn granule cells leads to impaired dendritic 87 
maturation (Sun et al., 2009). 88 
It is difficult to disentangle which Alzheimer’s disease-related pathological features directly 89 
contribute to seizure development and which are by-products of a hyperexcitable 90 
environment. Therefore, we investigated temporal lobe epilepsy-related epileptogenesis in 91 
ArcticAβ mice (Knobloch et al., 2007), overexpressing human amyloid precursor protein 92 
transgene containing the Swedish and Arctic mutations. The Swedish mutation shifts the 93 
balance of the amyloid precursor protein cleavage towards the beta secretase pathway, 94 
increasing the levels of carboxy-terminal fragments and ultimately β amyloid peptides. The 95 
Arctic mutation increases the aggregation tendency of Aβ without affecting the secretases. 96 
5 
 
Since neuronal dysfunctions associated with Aβ pathology occur prior to plaque deposits 97 
(Billings et al., 2005; Busche et al., 2012; Kam et al., 2016), it is possible to separate the two 98 
phenomena. We monitored the clinical course of epileptogenesis induced by 99 
intrahippocampal injection of kainic acid (IHK) in young adult ArcticAβ mice and wildtype 100 
littermates. IHK induces a status epilepticus followed by a seizure-free 2-week latent period 101 
preceding SRS onset (Suzuki et al., 1995; Bouilleret et al., 1999; Riban et al., 2002), 102 
allowing to causally determine the role of early Alzheimer’s disease-related neurochemical 103 
alterations for epileptogenesis and development of temporal lobe epilepsy, as assessed by 104 
chronic intrahippocampal EEG recordings and immunohistochemical analysis. Finally, we 105 
tested the possible role of Aβ species and related fragments of the amyloid precursor protein 106 
(Benilova et al., 2012) by inactivating them intracerebrally with a neutralizing antibody. 107 
108 
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Materials and methods 109 
Mice 110 
All experiments performed for this study were carried out in accordance with the Swiss law 111 
on animal experimentation and approved by the Cantonal Veterinary Office of Zurich. 112 
ArcticAβ transgenic mice (Knobloch et al., 2007) and age-matched wildtype littermates were 113 
bred at the Laboratory Animal Sciences Center of the University of Zurich. They were 114 
genotyped by PCR analysis from ear biopsies. They were housed at standard conditions (20-115 
24℃; minimum 40% relative humidity) under a 12-hour light/dark cycle, with access to food 116 
and water ad libitum. Experiments were performed in males unless indicated otherwise and 117 
all group sizes are reported with the statistical analyses. 118 
Intrahippocampal kainic acid (IHK) injection 119 
At the age of 12-to-15-weeks, mice anaesthetized by inhalation of 2.5-3% isoflurane (Baxter) 120 
in oxygen were injected (Nanoject II, Drummond Scientific) with 70 nL kainic acid (5 mM in 121 
NaCl; Tocris biosciences) or an equivalent volume of NaCl into the right dorsal hippocampus 122 
(anteroposterior [AP] -1.8 mm, mediolateral [ML] -1.6 mm, dorsoventral [DV] -1.9 mm 123 
relative to Bregma) as described by (Bouilleret et al., 2000a). For analgesia, mice were i.p. 124 
injected with 1 mg/kg buprenorphine (Temgesic®, Reckitt Benckiser AG, Switzerland) prior 125 
and after surgery. For some experiments (indicated below), a protective dose of diazepam (5 126 
mg/kg) was administered immediately after the end of IHK injection.  127 
Intrahippocampal retrovirus injection 128 
Adult mice (2 months old) were anesthetized as described above. Retrovirus encoding 129 
enhanced green-fluorescent protein (eGFP; 1 μL) was bilaterally injected into the hilus of the 130 
dentate gyrus (AP -2.0 mm, ML +/- 1.5 mm, DV -2.3 mm relative to Bregma) and the tissue 131 
was collected at 21 or 42 days post injection (dpi). eGFP-encoding retrovirus was produced 132 
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“in house”, as described in (Deprez et al., 2016). HEK 293T cells were transfected with three 133 
different plasmids containing the capsid (CMV-vsvg), viral proteins (CMV-gag/pol) and the 134 
transgene (CAG-eGFP) under the control of the CAG promoter (including the CMV CMS 135 
enhancer and chicken β-actin promoter). 136 
Antibody injection 137 
A subset of mice was intracerebroventricularly injected with purified mouse anti-Aβ antibody 138 
(6E10, Aβ3–8, IgG1; Covance) or control immunoglobulin G (IgG; 4 mg/mL; kindly 139 
provided by Dr. Britta Engelhardt, Theodor Kocher Institute, University of Bern) for a local 140 
neutralization of soluble Aβ species (Sudduth et al., 2013). A bilateral infusion (5 μL each, 141 
500 nL/min, 10 min wait prior to needle retraction) into the lateral ventricles (AP -1.8 mm, 142 
ML +/-2.75 mm, DV -2.5 mm relative to Bregma) was performed under general anesthesia 3 143 
days prior to the IHK injection. The tissue was collected at 18 dpi (IHK injection) for 144 
histological analysis. 145 
Electrode implantation for EEG 146 
For EEG recordings, mice were implanted immediately after stereotactic injection of KA 147 
with a bipolar electrode into the same coordinates as the injection and a monopolar reference 148 
electrode was placed into the cerebellum of the left hemisphere. Two enamel insulated 149 
stainless steel wires were connected to a male connector and twisted to a bipolar electrode for 150 
EEG recordings (0.125 mm inner diameter, 0.15 mm outer diameter, distance between the 151 
tips = 0.4 mm; for details see (Arabadzisz et al., 2005)), while two gold wires were inserted 152 
into the neck muscles for EMG recordings (for details see (Palchykova et al., 2010)). 153 
Electrodes were connected through a board-to-board connector (M52-5050545, Harwin) and 154 
fixed to the skull by a combination of Prime&Bond (Dentsply) and Tetric EvoFlow (Ivoclar 155 
vivadent) while the entering electrode shaft was sheathed by Kwik-CastTM Silicone 156 
Elastomer (World Precision Instruments).  157 
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EEG recordings and analysis 158 
Mice were placed into custom-made recording cages within a Faraday cage. A custom-made 159 
vEEG system was used for continuous synchronous video and EEG recordings, consisting of 160 
a custom-made swivel, an amplifier and digitizer (AcqKnowledge MP100; Biopac Systems), 161 
infrared-switchable video cameras (Vivotek Inc., New Tapei City, Taiwan), NAS server 162 
(Synology), and a custom-made timer for synchronization (BASIC Stamp 2, Parallax Inc, 163 
Rocklin, CA, USA). EEG and EMG data was acquired at a sampling rate of 200 Hz. 164 
Continuous video-EEG (vEEG) recordings were acquired after the injection until 18 days 165 
post injection (dpi) or once at 21 dpi. To assess the acute response to IHK, vEEG recordings 166 
of the first 4 hours were manually analyzed (open source software Polyman, EDF+). The 167 
severity of behavioral seizures was categorized according to the Racine, Pinel and Rovner 168 
scale (Table 1) (Racine, 1972; Pinel & Rovner, 1978). For each day, one hour was analyzed 169 
during the activity phase (around 1 am) and during the resting phase (around 1 pm). For 170 
seizure quantification during the chronic phase, a three-hour recording (11 am to 2 pm) was 171 
analyzed. Seizures were defined as paroxysmal events lasting longer than 20 s that were 172 
separated by intervals of at least 1 s. The average frequency and duration of spontaneous 173 
recurrent seizures (SRS) was calculated for each mouse. 174 
Acute brain slice preparation 175 
3-month-old mice were anesthetized with sodium pentobarbital (Nembutal®; 50 mg/kg; i.p.) 176 
and decapitated. 300 µm – thick sagittal slices were cut on a vibratome (Leica VT 1200 S) in 177 
ice-cold cutting solution and then stored in ACSF at room temperature in an interface type 178 
holding chamber for at least 1 h. Cutting solution contained (in mM) NaCl 87, KCl 2.5, CaCl2 179 
0.5, MgCl 7, NaH2PO4 1.25, NaHCO3 25, glucose 10 and sucrose 75. ACSF contained (in 180 
mM) NaCl 120, KCl 3, CaCl2 2.5, MgSO4 2, NaH2PO4 1, NaHCO3 25, and glucose 20, and 181 
was bubbled with 95% O2, 5% CO2 (pH 7.4). 182 
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Field recordings 183 
For the recording of extracellular population spikes glass microelectrodes of approx. 1.5 MΩ 184 
were filled with saline and placed near the border of CA1 stratum radiatum. Population 185 
spikes were evoked at 0.05 Hz with two pulses (50 ms apart) through a bipolar stimulating 186 
electrode positioned in CA3. A 15 min stable baseline was acquired before the application of 187 
1µM KA for 10 min. The amplitudes of the population spikes were measured using Clampfit 188 
10 (Molecular Devices, LCC, Sunnyvale, California, United States). To evaluate changes 189 
induced by kainic acid (KA) application, mean baseline values (mean of all amplitudes 5 min 190 
before the application of KA, i.e. 15 consecutive responses) were compared to those elicited 191 
30 min after the washout of KA (mean of 15 consecutive responses). 192 
Patch clamp recordings 193 
For whole cell patch clamp recordings CA3 area was cut away. CA1 hippocampal cells were 194 
visualized with an upright microscope (Axioscope Examiner.A1, Carl Zeiss; 63x water 195 
immersion objective). Whole-cell pipettes were pulled from thin wall glass capillaries (1.5 196 
O.D. X 1.17 I.D., Harvard Apparatus, Massachusetts, USA) using a Zeitz DMZ Puller 197 
(Martinsried, Germany). Electrode resistances in the bath were 3–6 mV. Series resistance was 198 
monitored by a –5mV step, and cells were discarded if this changed significantly (~20%). 199 
The intracellular solution consisted of (in mM) CsCl 140, HEPES 10, EGTA 10, MgATP 2, 200 
Na3GTP 0.3, pH 7.3, 290 mOsM. Cells were clamped at a holding potential of –70 mV to 201 
register spontaneous postsynaptic currents (sPSC). Currents were recorded with a multiclamp 202 
700B (Molecular Devices, Pennsylvania, USA), and digitized at 10 kHz using a Digidata 203 
1550 digitizer (Molecular Devices) and Clampex 10.0 (MolecularDevices). Traces were 204 
recorded with pClamp 10 and analysis of sPSCs frequencies and amplitudes were performed 205 
with MiniAnalysis (Synaptosoft, New Jersey, USA). KA (250 nM) was added for 5 min. For 206 
each condition (i.e. before the addition of KA and in the presence of KA) traces of one-207 
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minute duration were used for statistical analysis. The one-minute period where the effect of 208 
KA was maximal, was chosen for the statistical analysis. 209 
RNA isolation and quantitative real-time PCR 210 
Adult mice were anesthetized, decapitated, brains were extracted rapidly on ice and 211 
hippocampus dissected. Whole cell RNA from brain tissue was extracted using NucleoSpin 212 
RNA kit (Macherey-Nagel). cDNA was prepared using random hexamer primer (Thermo 213 
Scientific) and MuLV Reverse Transcriptase (Thermo Scientific). 1 μg of total RNA was 214 
amplified in CFX384 Touch™ Real Time PCR detection system (Biorad) using the 215 
SYBRgreen PrecisionPLUS qPCR Mastermix (Primerdesign). The relative levels of each 216 
RNA sample were calculated by the 2-ΔΔCT method using Biogazelle, qBase plus software 217 
(Livak KJ, 2001) and were normalized to that of HPRT and eEF1a1 mRNA. Each CT value 218 
used for these calculations was the mean of triplicates of the same reaction. All primers were 219 
synthesized by Eurofins genomics. Sequences of all primers are listed in Table 2. 220 
5′-bromo-2′-deoxyuridine (BrdU) treatment 221 
Three weeks prior BrdU treatment, adult female mice were housed together (five per cage) 222 
and bedding containing male mouse urine was introduced to the cages to induce Lee-Boot 223 
and Whitten cycle-synchronizing effects. At the age of two months, mice received two 224 
intraperitoneal injections of 90 mg/kg BrdU (Sigma-Aldrich, #B5002, dissolved in 0.9% 225 
NaCl) on two consecutive days. The tissue was collected at 1 dpi to assess cell proliferation 226 
and at 28 dpi to evaluate cell survival and cell fate.  227 
Tissue preparation for immunohistochemistry 228 
Tissue was collected and prepared similar to the protocol of Notter et al. (2014). In brief, 229 
mice were anesthetized (Nembutal®; 50 mg/kg; i.p.) and perfused intracardially with 15–20 230 
mL ice-cold, oxygenated aCSF [containing (mM) NaCl 125, KCl 2.5, CaCl2 3.7, MgCl2 2, 231 
NaHCO3 26, NaH2PO4 1.25, glucose 25], pH 7.4, at a flow rate of 10–15 mL/min. The brain 232 
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was extracted and divided into 3 blocks: rostral, medial and caudal part. All three parts were 233 
immediately immersion-fixed for 3 hours in ice-cold fixative [4% paraformaldehyde 234 
dissolved in 0.15 M sodium phosphate buffer], pH 7.4, then rinsed with PBS (pH = 7.4) and 235 
cryoprotected overnight in 30% sucrose in PBS at 4°C. 236 
The fixed tissue was cut into 70-μm (dendritic morphology) or 40-μm (rest) thick serial 237 
coronal sections using a sliding microtome and collected in ice-cold PBS. For storage, 238 
sections were transferred to a cryoprotectant solution (50 mM sodium phosphate buffer, pH 239 
7.4, containing 15% glucose and 30% ethylene glycol; Sigma-Aldrich) and kept at -20°C. 240 
Immunohistochemistry 241 
Sections were washed three times in Tris buffer (50 mM Tris, 150 mM NaCl, 0.05% Triton 242 
X-100, pH 7.4) for 10 min each and incubated overnight at 4 ℃ under continuous agitation 243 
with primary antibodies (Table 3) diluted in Tris buffer containing 2% normal goat serum 244 
(NGS) and 0.2% Triton X-100. Sections were rinsed three times in Tris buffer and incubated 245 
with the secondary antibody solution (2% NGS, Tris buffer) for 30 min at room temperature 246 
with secondary antibodies raised in goat. For immunofluorescence, secondary antibodies 247 
conjugated to AlexaFluor-488 (Invitrogen) were diluted to 1:1000 and those conjugated to 248 
Cy3 or Cy5 (Jackson ImmunoResearch Laboratories) to 1:500. After washing three times in 249 
PBS, sections were mounted to gelatin-coated glass slides and cover-slipped using 250 
Fluorescence Mounting Medium (Dako). For immunoperoxidase staining, biotinylated 251 
secondary antibodies (Jackson ImmunoResearch Laboratories) were diluted 1:300 and after 252 
washing three times in Tris buffer, incubated with avidin-peroxidase-complex solution 253 
(Vectastain Elite kit, Vector Labs) at room temperature. After washing them again three 254 
times in Tris buffer, sections were stained by combining 3,3-diaminobenzidine (DAB; 255 
Sigma–Aldrich Inc.) in Tris buffer (pH 7.7) with hydrogen peroxide for 5-15 min. Sections 256 
were immediately transferred to ice-cold PBS and washed three times. Finally, sections were 257 
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mounted onto gelatinized glass slides, air-dried overnight, dehydrated through ethanol, 258 
cleared in xylene and coverslipped with resinous (Eukitt™; Sigma-Aldrich) mounting 259 
medium. 260 
Nissl staining 261 
The IHK-induced pattern of degeneration and the placement of EEG electrodes were 262 
determined by Nissl staining with Cresyl violet. To this end, slides with air-dried sections 263 
were dipped in the following solutions: 5 min in dH2O, 5 min in filtered Cresyl violet 264 
solution (C18H15N3O3, M 321.34, Fluka BioChemika, Cat. no. 10510-54-0), 30 sec in dH2O 265 
and cleared in 96% ethanol containing 0.5% acetic acid until the desired coloration was 266 
obtained, 5 min in isopropanol, 5 min in isopropanol:Xylene (1:2) and 4 times dehydrated in 267 
xylene for 2 min. Finally, the slides were coverslipped with Eukitt.  268 
Experimental design and quantification 269 
All analyses were performed by an observed blinded to the genotype and/or age of the mice. 270 
Treatment (saline versus kainic acid) was not blinded due to obvious morphological 271 
alterations induced by kainic acid. 272 
Visual scoring and image acquisition 273 
For visual scoring of the neurodegenerative pattern (Nissl), 3-4 sections per mouse were 274 
examined using an Axioscop 2 microscope (Carl Zeiss) with bright-field illumination and 275 
either a 10x, 20x objective or 40x oil immersion objective. All images for display were 276 
acquired with a color digital camera (AxioCam MRc5) and the corresponding software 277 
AxioVision 4.5 (Zeiss).  278 
Densitometry analysis 279 
Immunoperoxidase staining (CD68, NPY) intensity was assessed by densitometry analysis 280 
using the MCID software (MCID Elite 6.0, InterFocus Imaging Ltd., Cambridge, UK). First, 281 
images were digitized using a precision illuminator (Northern light Model B95, Imaging 282 
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Research Inc., Brock University, St.Catharines, Canada) and CoolSnap cf photo-camera 283 
(Photometrics, Tuscon, AZ, USA) with a Micro-Nikkor (55 mm + 12 mm) objective (Nikon 284 
Corp.). Then, the grey values were calibrated (Kodak step tablet no. 310ST607) and the 285 
intensity was measured in the different regions of interest (Fig. 1A). To correct for variations 286 
in background staining, the intensity value was normalized to the intensity of the whole 287 
section and for each mouse, the intensity of a particular area was averaged over three to four 288 
equidistant coronal sections. 289 
Stereological analysis of macrophage-like cells 290 
The number of F4/80+ macrophage-like cells was determined stereologically in series of 291 
randomly sampled brain sections (three to four per animal, sampling fraction 1/12) using an 292 
Axioplan 2 bright-field microscope (Carl Zeiss AG, Feldbach, Switzerland) with 20x (air, 293 
NA 0.75) objective and an integrated digital camera (MicroFIRE, Optronics AG, Goldach, 294 
Switzerland). The size of the granule cell layer and molecular layer of the dentate gyrus as 295 
well as the number of macrophage-like cells within these outlined regions (Fig. 1B) were 296 
estimated using the Mercator software (Mercator Pro rev. 7.8.2, Explora Nova, La Rochelle, 297 
France). The macrophage-like cells were counted exhaustively and together with the 298 
estimated thickness averaged per animal. 299 
Quantification of cell proliferation and survival 300 
BrdU+ cells in the subgranular zone and granule cell layer of the dentate gyrus were counted 301 
in four to five sections per mouse in dorsal hippocampus using the Axioscop 2 (Carl Zeiss; 302 
40x oil-immersion lens, NA 1.3). Dorsal hippocampal volume was estimated using Mercator 303 
software (compare above). 304 
Sholl analysis 305 
Fluorescent Z-stacks (spaced by 0.7 μm) throughout the entire thickness of the section were 306 
acquired with a confocal microscope (LSM710) using a 40x oil immersion objective (NA, 307 
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1.4) and ZEN 2012 black edition (Carl Zeis MicroImaging GmbH, Goettingen, Germany) 308 
software. Images were analyzed with ImageJ (version 1.49o; Java 1.6.0_12 (Wayne Rusband, 309 
National Institutes of Health, USA). Sholl analysis (Sholl, 1953) (concentric circles spaced at 310 
10 μm intervals, centered on the cell body) was used to analyze the complexity of the 311 
dendritic trees. First, neurons were traced using NeuronJ plugin (NIH ImageJ; (Meijering et 312 
al., 2004)). Further Sholl analysis plugin (Anirvan Ghosh Laboratory, University of 313 
California, San Diego, La Jolla, CA, USA) was used to calculate the number of intersections 314 
between dendrites and concentric circles. For the number of intersections as a function of 315 
distance from the soma, area-under the curve (AUC) was calculated and used for further 316 
statistical analysis. Dendritic morphometry (primary dendrite length, total dendrite length) 317 
was assessed with the NeuronJ plugin. In total 14-36 cells from the groups of 5 to 8 mice per 318 
time point were quantified. 319 
Spine density 320 
Z-stacks for spine density morphology analysis of randomly selected eGFP-positive dendritic 321 
segments were obtained with a 40x oil immersion objective using a 2.7 digital zoom. Spines 322 
density quantification and spine type classification were performed using CellCounter 323 
(ImageJ). The length of each segment was measured and the number of spines/μm was 324 
quantified. 325 
Statistical analysis 326 
Data are presented as mean ± standard error of the mean (SEM). Statistical analyses for 327 
multiple group comparison were performed by a one-way or two-way ANOVA with a 328 
Bonferroni post-hoc test. An unpaired t test, two-tailed, was used to compare two groups 329 
(Prism software, GraphPad version 6). For kainic acid-induced LTP a two-way repeated 330 
measure ANOVA was performed with a Sidak´s multiple comparisons test. To compare the 331 
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distribution of spontaneous currents (inter-event interval and amplitude) a Kolmogorov–332 
Smirnov test was used (differences were considered significant if p<0.0001). 333 
334 
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Results 335 
Acquired epilepsy and increased seizure-associated mortality in ArcticAβ mice 336 
To determine whether an  Alzheimer’s disease-like predisposition prior to detectable plaque 337 
pathology renders the limbic neuronal network more vulnerable to excitotoxicity and affects 338 
the development of acquired epilepsy, 3-month-old ArcticAβ mice and wildtype littermates 339 
were injected intrahippocampally with kainic acid (IHK) (Fig. 2A). Upon recovery from 340 
anesthesia, IHK induces a status epilepticus with occasional convulsive seizures in wildtype 341 
mice. ArcticAβ mice exhibited a much more severe reaction, with numerous convulsive 342 
seizures causing acute mortality. Nevertheless, the characteristic neurodegeneration pattern 343 
seen 21 days post-injection (dpi) in this model (Bouilleret et al., 2000a; Bouilleret et al., 344 
2000b), with loss of pyramidal cells in CA1 and CA3c and loss of hilar mossy cells in the 345 
dentate gyrus was the same in both genotypes (Fig. 2B). The severity and region-specificity 346 
of the cell loss were not different between the genotypes. IHK-induced granule cell 347 
dispersion in the dentate gyrus was also similar in ArcticAβ and wildtype littermates, as 348 
determined by measuring the thickness of the granule cell layer (GCL; t20 = 1.13, P = 0.27) 349 
and the molecular layer (ML; t20 = 1.4, P = 0.18; unpaired two-tailed t-test) (Fig. 2C). The 350 
number of invading macrophages, which was shown to correlate with the extent of granule 351 
cell dispersion (Zattoni et al., 2011), did not differ between genotypes (ML: t20 = 1.9, P = 352 
0.07; GCL: t20 = 0.2, P = 0.85; unpaired two-tailed t-test). In line with observations about the 353 
neurodegenerative pattern induced by IHK, microglial activation was not altered by the 354 
ArcticAβ transgene in the injected hemisphere (Fig. 2D).  355 
IHK led to the development of acquired epilepsy (onset of spontaneous recurrent seizures, 356 
SRS) in both genotypes, with mice exhibiting similar seizure frequency three weeks after the 357 
injection (t7 = 0.04, P = 0.97; unpaired two-tailed t-test) (Fig. 2E). However, a fraction of 358 
ArcticAβ mice unexpectedly died during the latent phase, leading to a significantly different 359 
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survival probability upon IHK (𝜒𝜒2(1) = 13.4, P = 0.0003; Mantel-Cox test) (Fig. 2F). Thus, 360 
Alzheimer’s disease-like predisposition in 3-month-old ArcticAβ mice increases 361 
susceptibility towards IHK, possibly by altering the response to excitotoxicity and causing 362 
aberrant activity during early epileptogenesis, while having no effect on SRS frequency and 363 
associated histopathological alterations in surviving mutant mice. 364 
Increased response to excitatory stimulation in the hippocampal network 365 
To study the causes of differential impact of IHK-induced status epilepticus on the 366 
hippocampal neuronal network of ArcticAβ mice, we recorded field population spikes in the 367 
main hippocampal output region, CA1, in tissue slices (Fig. 3A). A current-voltage plot 368 
illustrates the significantly different slope (P < 0.01, F(1,16)  = 9.9) of recorded population 369 
spikes as a function of stimulus intensity in wildtype compared to ArcticAβ mice (Fig. 3B). 370 
This difference suggests that the strength of synaptic transmission in CA1 is reduced in 371 
ArcticAβ mice, which is consistent with previous findings in other AD transgenic mice 372 
(Palop et al., 2007).  373 
Kainic acid (KA) has recently been shown to induce an NMDA-independent form of long 374 
term potentiation (LTP) (Petrovic et al., 2017). Similarly, we observed that a 10-min 375 
application of KA (1 µM) produces a stable potentiation of CA1 population spikes, which 376 
remained unchanged for at least 30 min after the drug had been washed out, in both wildtype 377 
(98.7 % ± 0.9 before KA to 116.7 % ± 7.4 after 30 min washout, 9 slices from n = 7 different 378 
animals) and ArcticAβ mice (101.1% ± 3,36 before KA to 177.7 % ± 26.10 after 30 min 379 
washout, 6 slices from n = 5 different animals) (Fig. 3C). The KA-induced potentiation was 380 
significantly higher in ArcticAβ mice compared to wildtype littermates (Fig. 3D) (two-way 381 
repeated measure ANOVA; significant effect of treatment 30 min after wash-in, F(1,10) = 8.6, 382 
P < 0.01, and genotype, F(1,10) = 8.6, P < 0.05). The latter difference was due to the stronger 383 
effect of KA in slices of ArcticAβ mice (Sidak´s multiple comparison post-hoc test). 384 
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Although not significant, we observed a tendency towards reduced paired pulse ratio after 385 
KA in ArcticAβ mice (Fig. 3E), suggesting some degree of presynaptic involvement in their 386 
enhanced response to KA.  387 
Impairment of the inhibitory circuit in CA1 388 
In order to examine the response of the inhibitory CA1 microcircuit to KA application 389 
without interfering pharmacologically with KA receptors, we isolated the CA1 region from 390 
CA3 by cutting out the latter with a scalpel and performed whole cell patch clamp recordings 391 
of CA1 pyramidal cells (Fig. 4A). To measure predominantly GABA currents, we used an 392 
intracellular solution consisting of a high Cl ̅‾ concentration (see Materials and Methods). 393 
Most spontaneous events recorded were inhibitory (sIPSCs), as the addition of ionotropic 394 
glutamate receptor blockers did not change the frequency of baseline activity, whereas the 395 
application of 20 µM bicuculline blocked most spontaneous activity (data not shown). 396 
Therefore, we will henceforth refer to the recorded spontaneous events as sIPSCs.  397 
Hippocampal network hyperactivity is an early symptom in AD (Palop & Mucke, 2016), and 398 
an increase in inhibitory activity in the dentate gyrus of hAPPFAD mice has been postulated as 399 
a compensatory mechanism (Palop et al., 2007). We observed no difference in baseline 400 
frequency of sIPSCs between wildtype and ArcticAβ mice in CA1 cells, and only a small 401 
change in their amplitude. However, the application of 250 nM KA significantly diminished 402 
the frequency of events in the mutant, but revealed no genotype difference in their amplitude 403 
(Fig. 4B). In slices from wildtype mice, KA increased the frequency of sIPSCs (data not 404 
shown), as shown previously (Fisher & Alger, 1984). In line with this finding, we observed 405 
that the clustering of these events before and after KA application differed between 406 
genotypes. To quantify this phenomenon, clusters of activity were defined as groups of 407 
sIPSCs occurring within less than 100 ms from each other, and binned them into four main 408 
groups, containing up to 3 events, 4-6 events, 7-9 events or >10 events (Fig. 4C). ArcticAβ 409 
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mice showed more clusters with a higher number of events during baseline, which 410 
disappeared in the presence of KA, whereas the opposite occurred for wildtype mice. 411 
Severe status epilepticus and early seizure onset during epileptogenesis 412 
Having observed an increased mortality in ArcticAβ mice during early stages of 413 
epileptogenesis (Fig. 2F), we used video-EEG (vEEG) monitoring to determine whether 414 
ArcticAβ mice suffer from more severe seizures during status epilepticus and die from 415 
convulsive seizures during the latent phase (Fig. 5A). During the first four hours of status 416 
epilepticus, ArcticAβ mice had more severe behavioral seizures (stage 6-7 of the Racine-417 
Pinel-Rovner scale; Table 1) than wildtype littermates even after reducing the dose of KA by 418 
half to 2.5 mM (Fig. 5B; left panel). Tonic-clonic seizures (stage 8) were only observed in 419 
ArcticAβ mice (Fig. 2F), and were lethal in some cases. However, neither the number (Fig. 420 
5C) nor the duration (Fig. 5D) of seizures differed between genotypes. Mortality was a major 421 
confounding factor in our study, because it implied that ArcticAβ mice that survived the 422 
status epilepticus might have only mild lesions induced by KA. Therefore, we decided to 423 
administer all mice a protective dose of diazepam (5 mg/kg) immediately after the end of 424 
IHK injection (Fig. 5A). As expected, diazepam treatment strongly reduced seizure severity 425 
(stage 2-3 of the Racine-Pinel-Rovner scale; Fig. 5B; right panel) and frequency (convulsive: 426 
F1 = 52.94, P < 0.0001; non-convulsive: F1 = 6.16, P = 0.025; Fig. 4C), while having no 427 
effect on seizure duration (Fig. 4D). Moreover, diazepam treatment after IHK injection 428 
averted status epilepticus-associated mortality, but not mortality occurring during the latent 429 
phase (Fig. 5F). Thus, increased susceptibility to severe behavioral seizures can not only be 430 
evoked by a proconvulsant, but also by spontaneous aberrant network activity in a later stage 431 
of epileptogenesis. 432 
To determine whether abnormal EEG activity during early epileptogenesis is associated with 433 
mortality during the latent phase, we acquired continuous vEEG recordings during the 434 
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progress of epileptogenesis. As reported (Riban et al., 2002; Arabadzisz et al., 2005), 435 
wildtype mice exhibit initially low voltage spikes or sharp waves (200-800 μV, 1-3 Hz), 436 
whereas SRS (800-1500 μV, 3-5 Hz, duration > 20 s) appear two weeks after IHK injection 437 
(Fig. 5E). ArcticAβ mice, however, showed a mixture of low voltage spikes and sharp waves 438 
(200-800 μV, 1-3 Hz) up to 3-4 dpi, with a subsequent early onset of SRS-like events (800-439 
1500 μV, 3-5 Hz, duration 10 - 20 s) at 4-5 dpi (Fig. 5E). These early short SRS were 440 
progressively replaced by regular SRS (duration > 20 s) from 12 dpi on. Interestingly, 441 
mortality of ArcticAβ mice during the latent phase (Fig. 4F) was associated with early onset 442 
of SRS at 3 dpi (Fig. 5E). Thus, ArcticAβ mice are more susceptible to the development of 443 
seizures, even when they are “protected” with diazepam during the IHK-induced status 444 
epilepticus. These findings suggest that early onset of SRS in ArcticAβ mice is due either to a 445 
missing anticonvulsive protection or a premature proconvulsive environment during the 446 
otherwise seizure-free latent period. 447 
Gradual progression of neurodegeneration and microgliosis during 448 
epileptogenesis 449 
Neurodegeneration and inflammation play an important role in the pathogenesis of both AD 450 
(Heppner et al., 2015) and TLE (Vezzani & Viviani, 2015). To test whether the 451 
hyperexcitable phenotype observed in ArcticAβ mice accelerates the development of a pro-452 
epileptogenic lesion, we determined the course of neurodegeneration (data not shown) and 453 
microglial activation (CD68 immunoreactivity) in the dorsal hippocampus at different time-454 
points (1, 3, 6, 14 dpi) of epileptogenesis (Fig. 6 and Table 4). Cresyl violet staining in 455 
adjacent sections was used to assess the neurodegenerative pattern. As expected (Bouilleret et 456 
al., 1999), hilar cells in the dentate gyrus were lost and pyramidal cells in CA1 became 457 
pyknotic within 24 h. During the progression of epileptogenesis, pyramidal cells in CA1 and 458 
in CA3c gradually degenerated, starting at 3 dpi up to an almost complete disappearance at 459 
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14 dpi. Dentate gyrus GC dispersion was clearly evident at 14 dpi (data not shown) and 460 
progressed further at 21 dpi (Fig. 2B). Both genotypes showed a gradual increase of CD68-IR 461 
(a marker of microglia activation) compared to control animals over a two-week period in the 462 
ipsilateral hippocampus (in all layers of CA1, the stratum lacunosum moleculare, CA3c and 463 
the strati pyramidale and radium of CA3 a,b; Fig. 6 and Table 4). Microgliosis peaked 464 
between 1 and 6 dpi in the hilus and the stratum lucidum, while being very low in the 465 
molecular layer and GC layer. Interestingly, ArcticAβ mice exhibited a less enhanced CD68-466 
IR compared to wildtype mice in the stratum oriens of CA3a,b at 1 dpi, and at 6 dpi in the 467 
hilus of the ipsilateral hippocampus (Table 4). The contralateral hemisphere showed 468 
increased CD68-IR except in stratum pyramidale of CA1, the stratum lacunosum-moleculare, 469 
or CA3c (Fig. 6B). 470 
In addition, tissue of ArcticAβ mice that died during status epilepticus (~45 min after 471 
injection; Fig. 2F) was compared to a group of wildtype littermates perfused 45 min post-472 
injection (“SE group”). We evaluated whether these ArcticAβ mice belonged to a subgroup 473 
with particularly pronounced sequelae associated with the AD pathology (including ectopic 474 
cell death and aggravated inflammation). Cresyl violet (data not shown) and CD68-IR (Fig. 475 
6B) revealed no difference between genotypes or between hemispheres suggesting that 476 
neither an AD-like predisposition nor the IHK injection affected cellular integrity or 477 
microglial activation during early status epilepticus. Thus, the general progression of 478 
neurodegeneration and microgliosis does not reflect increased vulnerability to aberrant 479 
excitation and does not predict early onset of SRS in AD transgenic mice during IHK-480 
induced epileptogenesis. 481 
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Examining the course of epileptogenesis revealed an impaired upregulation of 482 
neuropeptide Y in ArcticAβ mice 483 
Neuropeptide Y has anticonvulsive properties and is immediately upregulated in mossy fibers 484 
after increased excitation (Guo et al., 2002; Tu et al., 2005; Gotzsche et al., 2012). Reduced 485 
NPY expression has been reported in patients (Beal et al., 1986; Minthon et al., 1990) and 486 
animal models of AD (Ramos et al., 2006). Therefore, we determined whether AD-like 487 
pathology in 3-month-old ArcticAβ mice interferes with seizure-induced upregulation of 488 
NPY in the dorsal hippocampus at different time-points (1, 3, 6, 14 dpi) of epileptogenesis.  489 
In contrast, epileptogenesis-associated increase in neuropeptide Y expression was altered in 490 
ArcticAβ mice (Fig. 7 and Table 5). In wildtype mice, neuropeptide Y-IR was increased 491 
bilaterally, reaching significance in a region- and time-dependent manner across the various 492 
regions of the hippocampal formation (Fig. 7B). The increase was seen in both the granule 493 
cells and mossy fibers, as well as in interneurons contralaterally in CA1 and CA3. In 494 
comparison, ArcticAβ mice only displayed a moderate increase of neuropeptide Y-IR at 1-3 495 
dpi ipsilaterally and at 1-14 dpi contralaterally in the hilus and CA3c (Fig. 7 and Table 5). In 496 
the so-called SE group, there was no difference between wildtype mice perfused 45 min after 497 
injection and ArcticAβ mice that died due to a severe status epilepticus (Fig. 7B). Thus, while 498 
status epilepticus provokes a transient increase in NPY in dorsal hippocampus of wildtype 499 
mice, peaking after 24 hours and gradually declining over two weeks, this mechanism seems 500 
to be partially impaired in ArcticAβ mice. In line with these findings, reduced neuropeptide 501 
Y expression has been reported in patients (Beal et al., 1986; Minthon et al., 1990) and 502 
animal models of Alzheimer’s disease (Ramos et al., 2006). 503 
Impairment of NPY expression as an early sequelae of AD pathology 504 
Interestingly, when we determined the hippocampal expression of markers involved in NPY 505 
signaling, ArcticAβ mice showed a significantly reduced expression of NPY at both three and 506 
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nine months of age (F(1,16) = 4.7, P = 0.047; two-way ANOVA, Bonferroni post-hoc test; Fig. 507 
8A). The NPY receptor 1 (YR1) expression was not affected (F(1,16) = 1.12, P = 0.3064; two-508 
way ANOVA; Fig. 8B), but ArcticAβ mice exhibited an increase in YR2 expression at nine 509 
months (F(1,16) = 1.12, P = 0.3064; two-way ANOVA; Fig. 8C) and a reduced YR5 expression 510 
at three months of age (F(1,16) = 1.12, P = 0.3064; two-way ANOVA; Fig. 8D). 511 
Previous studies in hAPP-J20 mice reported sprouting of NPY+ axons in the molecular layer, 512 
ectopic expression of NPY in mossy fibers, increased recurrent sprouting of mossy fiber 513 
collaterals (Timm staining or zinc transporter ZnT3-IR) and depletion of calbindin (CB) in 514 
GC (Palop et al., 2003; Palop et al., 2007). Increased levels of neuropeptides, most notably 515 
NPY in areas with high plaque burden, might reflect an attempt to counteract degeneration 516 
(Diez et al., 2003). Therefore, we determined whether NPY, ZnT3 and CB were changed in 517 
naive ArcticAβ mice before (three months) or after (nine months) occurrence of Aβ plaques 518 
(Fig. 8E-G). Compared to wildtype littermates (n = 6-8 / time point) no difference in NPY-IR 519 
was observed in the hilus and molecular layer of the dentate gyrus at either time-point (Fig. 520 
8E). Similarly, visual assessment of ZnT3-IR (Fig. 8F) and CB-IR (Fig. 8G) in GCs and in 521 
CA3 revealed no difference between genotypes. Together, these observations suggest that, 522 
albeit NPY and YR5 gene expression is reduced in ArcticAβ mice prior to occurrence of Aβ 523 
plaques, NPY-IR remains unaffected in 9-month-old mutants.  524 
Plaque pathology in Alzheimer’s disease and associated inflammatory response 525 
To confirm this conclusion, we verified in 3- and 9-month-old transgenic mice that the 526 
occurrence of plaques, microglial activation and expression of inflammatory markers occur as 527 
reported in the literature (Fig. 9). While intracellular Aβ deposits have been reported in 3-528 
month-old ArcticAβ mice (Knobloch et al., 2007), plaques, positive for 6E10 antibody, 529 
appear between seven and nine months of age with a progressive increase thereafter (Fig. 530 
9A). As seen by CD68-staining, Aβ plaques are surrounded by reactive microglia, but up to 531 
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the age of nine months there is no general microglia activation (Fig. 9B-C and Table 6). 532 
qPCR analysis of inflammatory cytokines in hippocampal samples revealed a decreased 533 
expression of IL-10 over time in both genotypes (two-way ANOVA, F(1,16) = 11, P = 0.004; 534 
Fig. 9D) and a different expression of IL-1β between genotypes (two-way ANOVA, F(1,16) = 535 
4.7, P = 0.047; Fig. 9E). No difference was detected in TNFα expression between wildtype 536 
and ArcticAβ mice at the age of 3 and 9 months (F(1,16) = 1.19, P = 0.291; two-way ANOVA; 537 
Fig. 9F), whereas the expression of triggering receptor expressed on myeloid cells 2 (Trem2) 538 
- a cell surface receptor expressed on microglia cells that was proposed to be important for 539 
phagocytosis and removal of apoptotic cells and β-amyloid without being accompanied by 540 
inflammation (Colonna & Wang, 2016) - was increased concomitant with the appearance of 541 
Aβ plaques in 9-month-old ArcticAβ mice (F(1,16) = 6.8, P = 0.02; two-way ANOVA, 542 
Bonferroni post-hoc test; Fig. 9G). 543 
Genotype-specific differences in hippocampal adult neurogenesis 544 
A large body of literature suggests a direct link between aberrant excitability and adult 545 
neurogenesis (Jessberger et al., 2005; Kralic et al., 2005; Ledergerber et al., 2006; Song et 546 
al., 2012; Sierra et al., 2015). We explored the hypothesis that ArcticAβ mice, like other AD-547 
transgenic mice (Sun et al., 2009), show impaired neurogenesis, which has been reported to 548 
exacerbate KA-induced status epilepticus (Iyengar et al., 2015). In order to assess 549 
proliferation and survival rate of newborn cells in the subgranular zone (SGZ) of the dentate 550 
gyrus, mice were injected with BrdU and tissue was collected at 1 and 28 dpi to assess 551 
proliferation and cell survival, respectively (Fig. 10A). At 1 dpi, ArcticAβ mice showed 552 
significantly more BrdU+ cells in the SGZ compared to wildtype littermates (14039 ± 1243 553 
cells/mm3, N = 8; 10415 ± 728 cells/mm3, N = 8; data shown as mean ± SEM; P = 0.03, 554 
paired, two-tailed Student’s t-test), while there was no difference between genotypes at 28 555 
dpi (ArcticAβ: 2663 ± 261.8 cells/mm3, N = 9; wild-type: 3384 ± 491 cells/mm3, N = 9; data 556 
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shown as mean ± SEM; P = 0.21, paired, two-tailed Student’s t-test) (Fig. 10B). To determine 557 
the fate of BrdU+ cells at 28 dpi, we used neuronal (NeuN) or astroglial (GFAP) markers. In 558 
both genotypes a similar proportion of neuronal (NeuN/BrdU; wildtype: 89.4% ± 2.6%, N = 559 
9; ArcticAβ: 91.5% ± 3.5%, N=7) and astroglial (GFAP/BrdU; wildtype: 7.5% ± 2.5%, N = 560 
9; ArcticAβ: 5.9% ± 3.1%, N=7) progenitors were observed. Further, we examined the 561 
morphological development of immature (21 dpi) and mature (42 dpi) newborn neurons 562 
infected with a retrovirus expressing eGFP (Fig. 10C). Sholl analysis of adult-born GC at 21 563 
and 42 dpi revealed a tendency towards a reduced dendritic arborization between genotypes 564 
(Fig. 10D). However, further away from the soma, starting from 150μm, this difference was 565 
statistically significant at both 21 dpi (wildtype: 197.4 ± 31, N = 27; ArcticAβ at 21 dpi: 70 ± 566 
23, N = 14; P = 0.0094) and 42 dpi (wildtype: 359 ± 25, N=36; ArcticAβ: 258 ± 34, N=17; P 567 
= 0.0221; data displayed as area under the curve (AUC), mean ± SEM, paired, two-tailed 568 
Student’s t-test). Moreover, dendritic spine density was assessed and spines were classified in 569 
three subgroups (Fig. 10E). Overall spine density was significantly reduced in ArcticAβ mice 570 
at 21 dpi, with a specific reduction in thin spines. At 42 dpi, adult-born GC of ArcticAβ mice 571 
had significantly fewer stubby spines, while overall spine density was normalized. At both 572 
time-points, the proportion of spine types did not differ between animals. Although ArcticAβ 573 
mice had increased cell proliferation, the survival of both neuronal and glial progenitors 574 
seems to be reduced. Together with the reduced spine density in adult-born GC, these 575 
findings point towards a slight impairment of neurogenesis in 3-month-old ArcticAβ mice.  576 
Epileptogenesis-associated changes in hippocampal adult neurogenesis 577 
Neuronal stem cells divide into reactive astrocytes after IHK-induced status epilepticus, 578 
which ultimately leads to depletion of the neuronal stem cell pool and thereby, long-term 579 
impairment of adult neurogenesis (Sierra et al., 2015). To evaluate whether the alterations in 580 
proliferation and survival of progenitor cells in ArcticAβ mice accelerates the disruption of 581 
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neurogenesis during epileptogenesis, we analyzed DCX+ neuronal precursor cells at different 582 
time points (1, 3 , 6, 14 dpi) after IHK-induced status epilepticus (Fig. 11). DCX-IR 583 
decreased over time in both genotypes (two-way ANOVA, F(4, 40) = 38.9, P < 0.0001), and at 584 
a similar rate (Fig. 11A), as previously described in wildtype mice (Ledergerber et al., 2006). 585 
In controls, DCX+ cells, which are located close to the SGZ, send their dendrites into the 586 
molecular layer (Fig. 11A). Ipsilaterally, DCX+ processes disappear within 1 dpi, followed 587 
by a gradual disappearance of most cell bodies until 14 dpi. Contralaterally, DCX-IR 588 
remained unchanged until 6 dpi, and increased at 14 dpi. However, there was no difference 589 
between ArcticAβ mice and wildtype littermates. Similarly, both genotypes exhibited a 590 
comparable number of ectopic cells in the hilus (two-way ANOVA, F(11, 96) = 1.20, P < 591 
0.2964; Fig. 11B). In addition, ArcticAβ mice that died during status epilepticus did not 592 
differ from wiltype mice at 45 min post-injection with regard to DCX-IR or number of 593 
ectopic cells in the ipsilateral hilus (Fig. 11B). Taken together, the decline of neuronal 594 
progenitors after IHK-induced epileptogenesis follows a similar course in both genotypes. 595 
Soluble Aβ species contribute to the early onset of SRS during IHK-induced 596 
epileptogenesis 597 
Given that 3-month-old ArcticAβ mice do not show any plaques while constitutively 598 
overexpressing Aβ (Knobloch et al., 2007), we aimed to determine whether a clearance of 599 
soluble Aβ species and other fragments of the amyloid precursor protein might prevent the 600 
early onset of SRS in these mice. Three days prior to the IHK-induced status epilepticus, a 601 
mouse anti-Aβ antibody (6E10) or a control IgG were bilaterally injected into the lateral 602 
ventricles on the anterio-posterior plane of the IHK-injection side (Fig. 12A). Mice were then 603 
subjected to continuous vEEG during the next three weeks and seizure-like events were 604 
analyzed. Interestingly, injection of Aβ antibody alleviated the epileptic phenotype in 605 
comparison to an IgG injection in ArcticAβ mice (Fig. 12B). While three out of four IgG-606 
27 
 
injected ArcticAβ mice exhibited regular SRS from 3-4 dpi, as shown above (Fig. 4E), and 607 
one died from convulsive seizures at 12 dpi, the four mice treated with Aβ antibody only had 608 
a few SRS-like events and did not develop SRS during the first 14 days post-IHK. In 609 
addition, several mice injected with IgG showed tonic-clonic seizures whereas only one of 610 
the ArcticAβ mice injected with Aβ antibody had a convulsive seizure. One IgG-injected 611 
animal exhibited multiple short clusters of spikes that were considered to be SRS-like events 612 
(B1 in Fig. 12B). In contrast, one mice injected with Aβ antibody had a transient phenotype, 613 
with only two short SRS-like events at 3 dpi, while otherwise the EEG pattern was 614 
characterized by short clusters of spikes (B2 in Fig. 12B). Noteworthy, this mouse (C3 in Fig. 615 
12C), like the others, revealed the normal neurodegenerative pattern of the IHK-model 616 
(Bouilleret et al., 1999): degeneration of pyramidal cells in CA1 and CA3c, as well as of hilar 617 
cells in the dentate gyrus (Fig. 12C). In the eight mice administered with IgG or Aβ 618 
antibodies, no GC dispersion was seen, suggesting a potential interference between the two 619 
processes. Taken together, antibody-mediated neutralization of soluble Aβ species and other 620 
fragments of the amyloid precursor protein prevented the occurrence of SRS during the latent 621 
phase in 3-month-old ArcticAβ mice, suggesting that Aβ overexpression promotes 622 
epileptogenesis in these mice. 623 
624 
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Discussion 625 
This study was designed to determine whether neuronal hyperactivity, which is characteristic 626 
of several mouse models of familial AD, might lead to the generation of SRS. To this end, we 627 
used the IHK-model of temporal lobe epilepsy to determine whether transgenic expression of 628 
mutant APP in Arctic Aβ mice facilitates the progression of epilepsy and seizure onset. The 629 
results indicate that ArcticAβ mice exhibit increased susceptibility towards KA-induced 630 
hyperexcitability long before the stage of plaque formation. In these mice, the strength of 631 
GABAergic inhibition in the CA1 region is reduced and LTP is facilitated. Hyperexcitability 632 
in ArcticAβ mice leads to lethal convulsions during status epilepticus, which can be 633 
prevented by diazepam. In addition, it leads to the premature onset of SRS, and in some mice, 634 
to lethal convulsive seizures during the first three weeks post-IHK. This increased seizure 635 
susceptibility does not correlate with aggravated neurodegeneration, altered synaptic 636 
reorganization, immune responses or adult neurogenesis, but is paralleled by a reduced gene 637 
expression of NPY − a neuropeptide with anti-convulsant properties − and, most strikingly, 638 
reduced upregulation of NPY-IR in granule cells of the dentate gyrus. Importantly, 639 
hyperexcitability could be reversed upon neutralization of soluble Aβ species and other 640 
fragments of the amyloid precursor protein, arguing against constitutive adaptation 641 
mechanisms and in favor of a direct effect of Aβ species on synaptic, in particular 642 
GABAergic, transmission in the hippocampal formation. Therefore, our results are consistent 643 
with the hypothesis that seizures occurring in AD-patients, especially at early disease stages, 644 
are due to synaptic and neuronal effects of Aβ species. 645 
Hyperexcitability and epileptogenesis in AD mouse models 646 
AD is associated with network abnormalities, characterized by hypersynchrony and altered 647 
oscillatory activity that precede clinical disease onset (Palop & Mucke, 2016). Epileptiform 648 
activity has been reported in AD patients, in particular at early stages (Amatniek et al., 2006; 649 
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Scarmeas et al., 2009; Vossel et al., 2013; Vossel et al., 2016) and with a higher incidence 650 
during sleep (Horvath et al., 2017; Lam et al., 2017). Recent studies confirmed that 651 
hyperexcitability in AD mouse models appears prior to plaque and tangle pathology. For 652 
example, 25% CA1 pyramidal cells are hyperactive in mice overexpressing human APP with 653 
a Swedish mutation and mutant human presenilin 1 (APP/PS1) already at an age of 1.5 654 
months (Busche et al., 2012). This neuronal dysfunction was rescued by acute treatment with 655 
a γ-secretase inhibitor and neuronal hyperexcitability was induced in wildtype mice by 656 
applying soluble Aβ. Although which cell types are most vulnerable and therefore first 657 
affected by Aβ is not fully clarified, interneurons are among the earliest cells affected. 658 
Axonal loss of SOM+ interneurons in CA1 was reported in APP/PS1 mice at pre-plaque 659 
stage, and at later stages correlating with proximity to Aβ plaques (Schmid et al., 2016), 660 
suggesting that GABAergic boutons are affected early by soluble Aβ species. In line with 661 
these findings, we found in young ArcticAβ mice that decreased synaptic strength and 662 
increased KA-induced LTP are associated with changes in sIPSCs in CA1 pyramidal cells. 663 
Unlike previous studies using mice overexpressing human APP with a Swedish mutation 664 
(hAPP-J20) at plaque-bearing stage (Palop et al., 2007), we did not find any increase in 665 
inhibitory activity at baseline. As suggested by (Palop et al., 2007), increased inhibitory 666 
activity might be a compensatory response to an hyperexcitable phenotype. Such 667 
compensatory mechanism might explain clustered sIPSCs at baseline in ArcticAβ mice (Fig. 668 
5). Ectopic expression of NPY and sprouting of GABAergic axons has been reported in 669 
different AD mouse models (Chin et al., 2004; Palop et al., 2007; Roberson et al., 2007). Our 670 
results indicate that these effects differ between models, especially in the timing of their 671 
appearance. Nevertheless, plaque-independent Aβ toxicity appears as a predominant feature 672 
altering local inhibitory circuits and increasing network excitability during early stages of the 673 
AD pathogenesis. Another factor that could have played a major role to explain the 674 
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hyperexcitability phenotype of Arctic Aβ mice, as well as early SRS onset, are potential 675 
differences in adult neurogenesis (Sun et al., 2009; Sierra et al., 2015). However, our results 676 
reveals only minor genotype-dependent changes in adult neurogenesis, which are not 677 
exacerbated upon IHK, making this hypothesis unlikely in our view. 678 
Increased susceptibility to induced seizures have been reported in different mouse models of 679 
AD (Palop et al., 2007; Roberson et al., 2007; Roberson et al., 2011; Sanchez et al., 2012; 680 
Verret et al., 2012; Kam et al., 2016). AD transgenic mice show age-dependent, and therefore 681 
disease-stage-dependent, occurrence of SRS with hippocampal origin (Palop et al., 2007; 682 
Minkeviciene et al., 2009; Kam et al., 2016). In our model, it is unclear which mechanisms 683 
underlie the development of SRS. We have shown previously that the latent period can be 684 
massively curtailed in mutant mice lacking lymphocytes (RAG1-knockout), which exhibit 685 
SRS within 24 h of IHK (Zattoni et al., 2011; Deprez et al., 2016). Our present results 686 
indicate a key role for soluble Aβ species, but the reduced overexpression of NPY in mutant 687 
mice compared to their wildtype littermates might also be an important contributing factor, 688 
along with the differential regulation of cytokines seen in our qPCR analysis.  689 
The role of NPY during epileptogenesis 690 
A body of literature examined the effect of NPY on modulating excitatory transmission and 691 
its role during different stages of epileptogenesis (Baraban, 2002; El Bahh et al., 2005). 692 
Erickson et al. (1996) reported that NPY-deficient mice are more susceptible to seizures 693 
induced by the GABAergic antagonist pentylenetetrazole (PTZ). Moreover, status epilepticus 694 
induced by repeated intraperitoneal injection of low dose kainic acid led to convulsive 695 
seizures in both genotypes at a similar concentration and within the same latency, but being 696 
lethal for 90% NPY-deficient mice compared to 22% wildtype littermates (Baraban et al., 697 
1997). Similarly, Y5R-deficient mice are more susceptible to KA, having more severe 698 
seizures and increased mortality (Marsh et al., 1999). Here, we found a similar phenotype 699 
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after IHK in young ArcticAβ mice accompanied by weaker expression of NPY and Y5R at 700 
the age of injection (Fig. 6). In contrast, NPY application (Woldbye et al., 1996; Baraban et 701 
al., 1997; Woldbye et al., 1997; Vezzani et al., 1999) or hippocampal overexpression of NPY 702 
and Y2R or Y5R using rAAV vectors (Richichi et al., 2004; Sorensen et al., 2009; Woldbye 703 
et al., 2010; Gotzsche et al., 2012) were shown to have an alleviating effect on electrically or 704 
chemically induced acute seizures. In particular, seizures of higher severity and seizure-705 
associated death were reduced upon activation of NPY signaling, while mild seizures 706 
remained unchanged. We likewise found no difference in the latency, number or duration of 707 
non-convulsive seizures in ArcticAβ mice during IHK-induced status epilepticus (Fig. 4). 708 
Moreover, at nine months of age, hippocampal Y2R expression is increased in ArcticAβ 709 
mice, similar to plaque-bearing hAPP-J20 mice (Palop et al., 2007), suggesting a 710 
compensatory mechanism after months of increased excitability.  711 
Although, the similarities between NPY-deficient animals and ArcticAβ mice are compelling, 712 
additional experiments are needed to evaluate if the decrease in NPY expression is directly 713 
responsible for the hyperexcitable phenotype of the AD model. To this end, it would be 714 
interesting to test whether neutralization of soluble Aβ species (e.g., with the 6E10 antibody) 715 
would restore NPY expression and signaling in ArcticAβ mice, and thereby ameliorate the 716 
excitability in vivo and in slices. 717 
The role of inflammation during epileptogenesis 718 
Perhaps the least expected finding of this study is that inflammation that accompanies 719 
neurodegeneration in the dorsal hippocampus after IHK was not more severe in ArticAβ 720 
mice, despite on-going stimulation of innate immunity by increased Aβ species and their 721 
accumulation in the brain (Knobloch et al., 2007). In our previous work in RAG1-KO mice 722 
(Zattoni et al., 2011), we showed that in the absence of adaptive immunity by T and B 723 
lymphocytes, IHK causes a stimulation of innate immunity mediated by neutrophils, leading 724 
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to extensive neurodegeneration in CA1-CA3 and eventually complete atrophy of the injected 725 
hippocampus. We also observed that this phenotype is accompanied by a dramatic shortening 726 
of the seizure-free latent phase that follows IHK, with RAG1-KO mice exhibiting SRS at 1-2 727 
dpi (Zattoni et al., 2011). Therefore, the disrupted balance between adaptive and innate 728 
immunity induces a condition in the brain of IHK-treated mice that favors SRS onset, 729 
presumably mediated by inflammation-related secreted or blood-born factors. Our present 730 
results show that the AD-like predisposition in ArticAβ mice also induces a condition that 731 
favors the occurrence of SRS during the latent phase, which is due, at least in large part to Aβ 732 
overexpression in the brain, and which does not stimulate further inflammatory mechanisms 733 
that would aggravate neurodegeneration. Both studies relativize the importance of neuronal 734 
circuit reorganization that takes place during the latent phase for SRS onset. Rather, they 735 
favor the view that the latent phase is seizure-free because of unknown protective 736 
mechanisms preventing seizure onset. These mechanisms can be overruled by immune 737 
factors or by hyperexcitability. 738 
Therefore, despite the fact that temporal lobe epilepsy and AD share common pathogenic 739 
mechanisms and exhibit comparable alterations in inhibitory neuronal networks in the 740 
hippocampal formation, as outlined in the Introduction, there appears to be little cross-over 741 
between the two disease conditions. In AD patients, like in Artic Aβ mice subject to IHK, 742 
epileptogenic activity and unprovoked seizures are most likely related to toxic Aβ species 743 
affecting synaptic transmission and favoring a state of chronic hyperexcitability. Unravelling 744 
the exact mechanisms by which these Aβ species affect synaptic GABAergic transmission in 745 
AD and in Artic Aβ mice, and in particular, whether this alterations involves NPY signaling, 746 
will contribute to better understand the prevalence of epileptic seizures in AD. 747 
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BrdU 5′-bromo-2′-deoxyuridine  764 
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AUC area under the curve  766 
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dpi days post injection  768 
GCL granule cell layer  769 
HL hilus  770 
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IgG immunoglobulin G  771 
icv intracerebroventricularly  772 
IHK intrahippocampal injection of kainic acid  773 
KA kainic acid  774 
LTP long term potentiation  775 
ML molecular layer  776 
NPY Neuropeptide Y  777 
NGS normal goat serum  778 
PTZ pentylenetetrazole  779 
sIPSCs spontaneous inhibitory postsynaptic currents  780 
sPSC spontaneous postsynaptic currents  781 
SRS spontaneous recurrent seizures  782 
SEM standard error of the mean  783 
SLM stratum lacunosum moleculare  784 
SO stratum oriens  785 
SP stratum pyramidale  786 
SR stratum radiatum  787 
SGZ subgranular zone  788 
Trem2 triggering receptor expressed on myeloid cells 2  789 
vEEG video-EEG 790 
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Figure legends 1145 
Figure 1 1146 
Area selection in histological sections for quantitative analysis. A, For densitometry 1147 
analysis, square boxes were placed in different layers of the dorsal hippocampus. B, For 1148 
stereological analysis, the molecular (ML) and the granule cell layer (GCL) of the dentate 1149 
gyrus were outlined. CA1, cornu ammonis subfield 1; SO, stratum oriens; SP, stratum 1150 
pyramidale; SR, stratum radiatum; SLM, stratum lacunosum moleculare; HL, hilus.  1151 
Figure 2 1152 
Increased response of ArcticAβ mice to IHK-induced epilepsy. A, Schematic 1153 
representation of the experimental design to assess acquired epilepsy. Kainic acid injection 1154 
and electrode implantation were performed in the right dorsal hippocampus, while EEGs 1155 
were recorded and tissue was collected for histological analysis at 21 dpi. B, Cresyl violet 1156 
staining of the ipsilateral hippocampus. Neurodegeneration in CA1, CA3c, and the hilus, 1157 
along with the dispersion of dentate granule cells, show a similar pattern in both IHK-injected 1158 
(SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; SLM, stratum lacunosum 1159 
moleculare; ML, molecular layer; GCL, granule cell layer; HL, hilus). C, F4/80+ 1160 
macrophages invading the ipsilateral dentate gyrus and the dispersion of dentate granule 1161 
cells. Stereological quantification of F4/80+ macrophages and measuring the layer thickness 1162 
of GCL and ML revealed no differences between genotypes (n = 6/genotype; 3-4 sections; 1163 
unpaired t-tests). D, Densitometric analysis of CD68 staining. Microglial activation was 1164 
increased 3 weeks after IHK injection in the ipsilateral hemisphere of both genotypes (n = 1165 
6/genotype; 3-4 sections; ***P < 0.0001, two-way ANOVA). E, Frequency of spontaneous 1166 
recurrent seizures (SRS). Both genotypes show a similar number of seizures three weeks after 1167 
IHK. Representative traces of intrahippocampal recordings reveal a high frequency of SRS in 1168 
the IHK model of acquired epilepsy (box outlines 10 s and 15 mV). F, Survival curve during 1169 
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epileptogenesis. ArcticAβ mice (n = 20) exhibit an increased mortality rate during the status 1170 
epilepticus and during the transition from the latent to the chronic period with SRS in 1171 
comparison to their wildtype littermates (n = 8) (***P = 0.0003, Mantel-Cox test). 1172 
Quantitative data represent mean ± SEM. Scale bars, 150 μm. 1173 
Figure 3 1174 
Decreased synaptic strength and increased KA-induced LTP in slices of ArcticAβ mice. 1175 
A, Schematic diagram showing electrode placement (Stim = bipolar stimulation electrode, 1176 
Rec = recording electrode) and hippocampal regions (S. coll = Schaffer collateral, DG = 1177 
dentate gyrus, CA1 and 3 = areas Cornu Ammonis 1 and 3 respectively). B, Current - voltage 1178 
relationship. ArcticAβ mice show a decreased synaptic strength compared to wildtype 1179 
littermates (**P < 0.01). Linear regression lines used for statistical comparison are dashed. C, 1180 
KA-induced LTP is more pronounced in ArcticAβ mice. Upper inset: representative traces of 1181 
population spikes before (black traces) and 30 min after (blue trace) a 10-min application of 1 1182 
µM KA. Paired pulses were given 50 ms apart. Stimulation artifacts were removed for visual 1183 
clarity. D, Percent change per cell before and 30 min after a 10-min application of 1 µM KA. 1184 
The increase in PS amplitude is significant for both groups after application of 1µM KA (P = 1185 
0.02, two-way repeated measure ANOVA), and between wildtype and ArcticAβ mice in the 1186 
degree of potentiation after a 30-min washout period (P = 0.01, two-way repeated measure 1187 
ANOVA). E, Paired-pulse ratio before and 30 min after a 10-min application of 1 µM KA. 1188 
Quantitative data represent mean ± SEM. 1189 
Figure 4 1190 
Reduced frequency of spontaneous inhibitory currents after KA application in slices of 1191 
ArcticAβ mice. A, Schematic diagram of a hippocampal slice after removal of the CA3 area. 1192 
B, Top inset: representative traces. Bottom graphs: Cumulative frequency distribution plots 1193 
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illustrating the frequency and amplitude of sIPSCs. Frequency of events is similar in wildtype 1194 
and ArcticAβ mice, but a 5-min application of KA decreases the inter-event interval in 1195 
ArcticAβ mice significantly (P < 0.0001, Kolmogorov–Smirnoff test). The sIPSC amplitude 1196 
is higher in ArcticAβ mice under baseline conditions (P < 0.0001, Kolmogorov–Smirnoff 1197 
test), but not after KA application. C, Distribution of clustered activity, consisting of events 1198 
that are separated by <100 ms. KA uncovers clusters with a higher number of events in 1199 
wildtype mice, whereas the opposite is found in ArcticAβ mice. (n = 4-5 mice/genotype). 1200 
Figure 5 1201 
Severe status epilepticus and early onset of SRS in ArcticAβ mice. A, Schematic 1202 
representation of the experimental design to monitor EEG activity during early 1203 
epileptogenesis. Continuous vEEG recordings were performed for 18 days after IHK 1204 
injection. B, Percentage of convulsive seizures with severity 2-8 according to the Racine-1205 
Pinel-Rovner scale during status epilepticus (Table 1). While ArcticAβ mice had more severe 1206 
seizures than wildtype mice after IHK injection (left), both genotypes had seizures with 1207 
severity 2-3 when treated with diazepam immediately after IHK injection (right). C, Total 1208 
number of convulsive (left) and non-convulsive (right) seizures during status epilepticus. 1209 
Diazepam significantly reduced the number of seizures (n = 4-6 mice/genotype; *P < 0.05, 1210 
****P < 0.0001, two-way ANOVA). D, Duration of convulsive behavioral seizures of 1211 
severity 2-8. There was no difference between genotypes (unpaired t-test). E, 1212 
Characterization of EEG patterns during the latent phase and beginning of chronic phase. An 1213 
early onset of short SRS-like events (defined as seizures with a duration of 10-20 s) occurred 1214 
in ArcticAβ mice at 5-8 dpi, while regular SRS were detected already at 3 dpi in the two mice 1215 
that died later on. Bottom traces depict representative examples of an SRS-like event (10 s < 1216 
Δt < 20 s), a regular SRS (≥ 20 s), and a tonic-clonic seizure leading to the death of the 1217 
animal. The spectrogram in the bottom left corner depicts the increase power in the frequency 1218 
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range of 20-100 Hz that is characteristic for seizures. F, Mortality rate for mice receiving 1219 
diazepam after IHK injection. With diazepam, status epilepticus-associated mortality in 1220 
ArcticAβ mice is abrogated, but some transgenic mice still died during the transition from the 1221 
latent to the chronic phase. Quantitative data represent mean ± SEM. 1222 
Figure 6 1223 
Reduced microgliosis in ArcticAβ mice during epileptogenesis. A, Representative images 1224 
of a marker for microglial activation (CD68) at 3, 6 and 14 dpi compared to control levels. 1225 
Scale bar, 250 μm. B, Densitometric analysis of CD68-IR in controls, in mice dying during 1226 
SE, as well as at 1, 3, 6, and 14 dpi. Both ArcticAβ mice (n = 4-5/ time point; red stars) and 1227 
wildtype littermates (n = 5-7/ time point; black stars) showed increased CD68-IR compared 1228 
to baseline control over the time course of early epileptogenesis in all layers of the ipsilateral 1229 
and in some layers of the contralateral hippocampus (*P < 0.05, **P < 0.01, ***P < 0.001, 1230 
****P < 0.0001; two-way ANOVA, Bonferroni post-hoc test). Analysis revealed a 1231 
significant group difference in the SO of CA3a,b and the hilus (green stars; compare Table 5 1232 
for details). Data represent mean ± SEM normalized to control for each region. 1233 
Figure 7 1234 
Impaired epileptogenesis-associated increase of neuropeptide Y in ArcticAβ mice. A, 1235 
Representative images of NPY staining of both genotypes comparing controls to mice 24 h 1236 
after IHK injection, the peak of the NPY upregulation. NPY-IR increases bilaterally 1237 
particularly in mossy fibers in the hilus and CA3. Scale bar, 250 μm. B, Densitometric 1238 
analysis of NPY-IR. IHK-injected mice show a significant increase in NPY levels in the ML, 1239 
GCL, HL and CA3c (black and red stars denote significant increase compared to control in 1240 
wildtype and in mutant mice, respectively. A comparison between genotypes (green stars) 1241 
reveals a significantly higher NPY-IR in the contralateral ML, HL, and CA3c as well as 1242 
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ipsilateral hilus of wildtype mice compared to ArcticAβ mice at 1 and 3 dpi (*P < 0.05, **P < 1243 
0.01, ***P < 0.001, ****P < 0.0001; two-way ANOVA, Bonferroni post-hoc test). 1244 
Quantitative data represent mean ± SEM.  1245 
Figure 8 1246 
Reduced neuropeptide Y expression is an early, pre-plaque sequelae of AD pathology. 1247 
A-D, Hippocampal expression of genes related to NPY signaling. The expression of NPY is 1248 
reduced in both 3- and 9-month-old ArcticAβ mice. Regarding NPY receptors, Npy1r 1249 
expression does not change, while the expression of Npy2r is increased at nine months and 1250 
Npy5r decreased at three months in ArcticAβ mice. (n = 4-7; *P < 0.05, **P < 0.01; two-way 1251 
ANOVA, Bonferroni post-hoc test). Quantitative data represent mean ± SEM. E, 1252 
Representative images of NPY-IR from 3-and 9-month-old wildtype and ArcticAβ mice. 1253 
Both genotypes reveal a similar NPY-IR at both time points. However, at nine months, three 1254 
of seven ArcticAβ mice reveal weak ectopic NPY-IR in mossy fibers visible in the hilus and 1255 
CA3a,b (arrowhead). F, Representative images of ZnT3-IR in 3-month-old wildtype and 1256 
ArcticAβ mice. There is no obvious axonal sprouting in the molecular layer in either 1257 
genotype (dashed box). G, Representative images of CB-IR in ArcticAβ mice and wildtype 1258 
littermates at three months. CB-IR in mossy fibers of CA3 (solid box) and in the granule cell 1259 
layer of the dentate gyrus (dashed box) are comparable between genotypes. Scale bars, 250 1260 
μm. 1261 
Figure 9 1262 
AD pathology and neuroinflammation. A, Representative images of tissue section stained 1263 
for β-amyloid (6E10-IR) from 15-month-old ArcticAβ and wildtype mice. Only transgenic 1264 
mice show plaques with their characteristic dense core morphology. The framed areas are 1265 
enlarged below. B, Representative images of CD68-IR in hippocampal sections from 3- and 1266 
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9-month-old ArcticAβ and wildtype mice. From their appearance in ArcticAβ mice at nine 1267 
months of age, plaques are surrounded by activated microglia, strongly positive for CD68 and 1268 
for 6E10; framed areas are enlarged below. C, Densitometric analysis of CD68-IR revealed 1269 
no difference between genotypes at both the pre-plaque (three months) and the early-plaque 1270 
(nine months) stage (n = 6/group; one-way ANOVA). C-E, Hippocampal expression of 1271 
cytokines IL10, IL1β, and TNF. While the expression of IL10 decreased over time (F(1,16) = 1272 
10.96, P = 0.0044) and IL1β differed between genotypes (F(1,16) = 4.655, P = 0.0465), TNF 1273 
expression did not change. F, The expression of Trem2, a marker for microglial phagocytosis 1274 
of β-amyloid peptides and apoptotic neurons without inflammation. ArcticAβ mice show a 1275 
significant increase in Trem2 expression at nine months of age, when β-amyloid plaques start 1276 
to appear. Scale bars, 250 μm.  1277 
Figure 10  1278 
Increased proliferation of newborn cells and reduced spine density in ArcticAβ mice. A, 1279 
Schematic representation of the experimental design to quantify newborn neurons. Mice 1280 
received BrdU injections for two consecutive days and brain tissue was collected at day 1 and 1281 
28 post-BrdU injection to evaluate cell proliferation and survival rate, respectively. B, 1282 
Quantification and representative images of BrdU immunostaining 1 and 28 days after the 1283 
last BrdU treatment. BrdU+ cells were located in the inner part of the GCL. Higher density of 1284 
BrdU+ cells was common in ArcticAβ mice at 1 dpi, but there were no differences at 28 dpi 1285 
(*P > 0.05, unpaired t-test). Scale bar, 160 μm. C, Schematic representation of the 1286 
experimental design to assess the dendritic arborization and spine density in adult-born 1287 
neurons. Brain tissue of both genotypes was collected 21 and 42 days after the 1288 
intrahippocampal injection of eGFP retrovirus. Quantification of dendritic arborization was 1289 
done by Sholl analysis measuring the number of intersections between eGFP+ dendrites and 1290 
virtual concentric circles centered on the cell body and spaced by 10 μm (bottom). D, 1291 
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Fluorescent images of representative examples of eGFP+ cells in each genotype at 21 and 42 1292 
dpi. Quantitative result of Sholl analysis showed no significant difference, but a trend 1293 
towards a reduced dendritic arborization in ArcticAβ compared to wildtype mice at 21 dpi. 1294 
There were no differences between genotypes at 42 dpi. Scale bar, 50 μm. E, Dendritic spine 1295 
classification analysis. Representative images of dendritic segments from eGFP expressing 1296 
GCs of wildtype and ArcticAβ mice at 21 and 42 dpi (scale bar, 5μm). Quantification of 1297 
mushroom, stubby, thin and overall spine density. ArcticAβ mice had significantly reduced 1298 
overall spine density and specifically thin spine density at 21 dpi and a reduced stubby spine 1299 
density at 42 dpi with no difference in the overall spine density (*P > 0.05, unpaired t-test). 1300 
There were no genotype differences for the proportion of the three types of spines. 1301 
Quantitative data represent mean ± SEM. 1302 
Figure 11 1303 
Gradual decrease of DCX+ progenitor cells in the ipsilateral SGZ during 1304 
epileptogenesis. A, Representative images of the neurogenic niche in the dentate gyrus of 1305 
wildtype and ArcticAβ mice. Over the course of epileptogenesis, DCX-IR in the SGZ of the 1306 
ipsilateral dentate gyrus gradually decreases in both genotypes up to almost complete 1307 
disappearance at 14 dpi while it remains unchanged on the contralateral side; A1, 1308 
densitometric analysis of DCX-IR confirming this result (***P < 0.001, ****P < 0.0001; 1309 
two-way ANOVA). Scale bar, 200 μm. B, Illustration and quantification of ectopic cells in 1310 
the hilus. B, Ectopic cells were detected by triple staining for DCX (neuronal marker), GFAP 1311 
(astrocytic marker) and CD68 (microglial marker). Left panel illustrates DCX-positive cells 1312 
in the hilus (arrowheads), which are not stained for GFAP and CD68 (right panel); examples 1313 
glial cells are indicated by arrows. B1, Quantification: the number of ectopic DCX-positive 1314 
cells in the hilus was similar between ArcticAβ mice and wildtype littermates (two-way 1315 
ANOVA). Quantitative data represent mean ± SEM. 1316 
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Figure 12 1317 
Clearance of soluble Aβ species ameliorates epileptic phenotype in 3-month-old 1318 
ArcticAβ mice during early epileptogenesis. A, Schematic representation of the 1319 
experimental design using the anti-Aβ antibody, 6E10. Three days before the unilateral IHK 1320 
injection, ArcticAβ mice were intracerebroventricularly (icv) injected with either 6E10 or 1321 
control IgG into both hemispheres near the dorsal hippocampus. After injecting IHK, mice 1322 
were monitored by vEEG to assess early onset of seizures in ArcticAβ mice. B, 1323 
Characterization of EEG pattern during the latent period. IgG-treated ArcticAβ mice 1324 
exhibited multiple SRS-like events and regular SRS, whereas mice injected with 6E10 1325 
showed only a few SRS-like events and short single or grouped spikes. B1, Example of IgG-1326 
injected mouse that had few SRS-like events within the analysis window; this animal had a 1327 
high number of spikes clusters that were sometimes followed by a SRS-like event occurring 1328 
outside of the window chosen for analysis. B2, This 6E10-injected mouse showed almost 1329 
exclusively single or grouped spikes with typical frequency and power characteristics 1330 
(spectrogram below). Scale bars, 500 μV, 5 s. C, Cresyl violet staining of the ipsilateral 1331 
hippocampus. C, Both IgG (C1) and 6E10 (C2) pre-treated animals showed the characteristic 1332 
neurodegenerative pattern seen after IHK injection, including degeneration of pyramidal cells 1333 
in CA1 (black arrowheads), CA3c (red arrowhead), and the cells in the hilus (yellow 1334 
arrowheads). The mouse illustrated in (B2) shared these typical histopathological hallmarks 1335 
(C3). Note the absence of GC dispersion in both groups. Scale bars, 150 μm. 1336 
1337 
56 
 
Table 1  Modified Racine Scale for Behavioral Seizures 1338 
Scale Stage Behavior 
Racine behavioral scale 
1 Oro-alimentary movements 
2 Head nodding 
3 Anterior limb clonus 
4 Dorsal extension (rearing) 
5 Loss of balance and falling 
Pinel and Rovner 
behavioral scale 
6 Repeated falling 
7 Strong jumping and running 
8 Stage 7 with tonic period 
The table was adapted from (Pinel & Rovner, 1978). 1339 
 1340 
1341 
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Table 2 List of primers for RT-qPCR 1342 
Target Forward sequence 5’ → 3’ Reverse sequence 5’ → 3’ 
Npy1r CAAGATATACATTCGCTTGA AGATTGTGGTTGCAGG 
Npy2r CCATCTTCCGGGAATAC TGACGTGGTTCCTCAG 
Npy5r TCAAGCGTTCCCTCAC ACAACAGGACATCATGC 
NPY TGGACTGACCCTCGCTCTAT TGTCTCAGGGCTGGATCTCT 
IL10 GGGAAGAGAAACCAGGGAGAT GCCACAGTTTTCAGGGATGA 
TREM2 GACCTCTCCACCAGTTTCTCC TACATGACACCCTCAAGGACTG 
TNFa AGCCAGGAGGGAGAACAGA CAGTGAGTGAAAGGGACAGAAC 
IL1β CAACCAACAAGTGATATTCTCCAT GGGTGTGCCGTCTTTCATTA 
Eef1a1 AAGCCCATGTGTGTTGAGAG CTCCAGCAGCCTTCTTGTC 
HPRT1 TCCTCCTCAGACCGCTTTT AGGTATACAAAACAAATCTAGGTCAT 
 1343 
 1344 
1345 
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Table 3 List of primary antibodies for immunohistochemistry 1346 
TARGET HOST SPECIES DILUTION CAT. NO. COMPANY / ORIGIN 
BrdU RAT 1:1000 OBT0030 Oxford Biotech 
CD68 RAT 1:2000 MCA1957GA AbD Serotec 
DCX GUINEA PIG 1:2000 AB2253 Merck Millipore 
F4/80 RAT 1:1000 b6640 Abcam 
GFAP RABBIT 1:20’000 Z334 Dako  
NPY RABBIT 1:1000 T-4069 Peninsula Lab. 
ZnT3 RABBIT 1:1000 197002 Synaptic Systems 
1347 
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Table 4 Statistical analysis of CD68-immunoreactivity after intra-1348 
hippocampal KA injection 1349 
 
Area Source of 
variance 
F value P value 
CA1 - SO Inter F (9, 80) = 1.486 P=0.1674 
Geno F (1, 80) = 3.723 P=0.0572 
Time F (9, 80) = 28.97 P<0.0001 
CA1 - SP Inter F (9, 80) = 1.282 P=0.2598 
Geno F (1, 80) = 3.237 P=0.0758 
Time F (9, 80) = 56.68 P<0.0001 
CA1 - SR Inter F (9, 80) = 1.338 P=0.2309 
Geno F (1, 80) = 4.28 P=0.0418 
Time F (9, 80) = 16.5 P<0.0001 
SLM Inter F (9, 80) = 0.7 P=0.7070 
Geno F (1, 80) = 1.492 P=0.2256 
Time F (9, 80) = 25.7 P<0.0001 
ML Inter F (9, 80) = 0.7915 P=0.6249 
Geno F (1, 80) = 0.06475 P=0.7998 
Time F (9, 80) = 12.13 P<0.0001 
GCL Inter F (9, 79) = 1.006 P=0.4425 
Geno F (1, 79) = 1.653 P=0.2023 
Time F (9, 79) = 8.004 P<0.0001 
HL Inter F (9, 79) = 1.738 P=0.0940 
Geno F (1, 79) = 4.389 P=0.0394 
Time F (9, 79) = 17.29 P<0.0001 
CA3c Inter F (9, 80) = 0.4201 P=0.9208 
Geno F (1, 80) = 2.593 P=0.1112 
Time F (9, 80) = 36.45 P<0.0001 
CA3a,b - SO Inter F (9, 77) = 2.006 P=0.0498 
Geno F (1, 77) = 1.286 P=0.2602 
Time F (9, 77) = 11.22 P<0.0001 
CA3a,b - SP Inter F (9, 77) = 0.7629 P=0.6506 
Geno F (1, 77) = 0.6179 P=0.4342 
Time F (9, 77) = 11.91 P<0.0001 
CA3a,b - SR Inter F (9, 77) = 0.9621 P=0.4777 
Geno F (1, 77) = 8.415 P=0.0048 
Time F (9, 77) = 11.61 P<0.0001 
Lucidum Inter F (9, 77) = 1.263 P=0.2707 
Geno F (1, 77) = 0.3842 P=0.5372 
Time F (9, 77) = 16.16 P<0.0001 
Densitometric analysis of CD68-IR was performed ispilaterally in the regions indicated at 1350 
four time-points post-IHK (1, 3, 6, and 14 dpi) as well as in controls. (see Fig. 6). Statistically 1351 
significant differences among genotypes are indicated in bold. SO, stratum oriens; SP, 1352 
60 
 
stratum pyramidale; SR, stratum radiatum; SLM, stratum lacunosum moleculare; ML, 1353 
molecular layer; GCL, granule cell layer; HL, hilus.  1354 
1355 
61 
 
Table 5 Statistical analysis of NPY-immunoreactivity 1356 
 
Area Source of 
Variance 
F value P value 
ML Inter F (9, 78) = 3.062 P=0.0034 
Geno F (1, 78) = 13.97 P=0.0004 
Time F (9, 78) = 8.029 P<0.0001 
GCL Inter F (9, 78) = 1.757 P=0.0901 
Geno F (1, 78) = 13.6 P=0.0004 
Time F (9, 78) = 15.85 P<0.0001 
HL Inter F (9, 78) = 4.85 P<0.0001 
Geno F (1, 78) = 67.47 P<0.0001 
Time F (9, 78) = 15.52 P<0.0001 
CA3c Inter F (9, 78) = 2.584 P=0.0116 
Geno F (1, 78) = 44.9 P<0.0001 
Time F (9, 78) = 12.48 P<0.0001 
CA3a,b - 
SO 
Inter F (9, 77) = 0.6358 P=0.7631 
Geno F (1, 77) = 2.937 P=0.0906 
Time F (9, 77) = 1.16 P=0.3322 
CA3a,b - 
SP 
Inter F (9, 77) = 0.7915 P=0.6250 
Geno F (1, 77) = 0.1921 P=0.6624 
Time F (9, 77) = 1.48 P=0.1703 
CA3a,b - 
SR 
Inter F (9, 77) = 0.4054 P=0.9286 
Geno F (1, 77) = 3.654 P=0.0597 
Time F (9, 77) = 0.8237 P=0.5963 
Lucidum Inter F (9, 77) = 0.5332 P=0.8461 
Geno F (1, 77) = 2.248 P=0.1379 
Time F (9, 77) = 3.357 P=0.0016 
Densitometric analysis of NPY-IR in ArticAβ mice and wildtype littermates was performed 1357 
in the regions indicated at five time-points post-IHK (see Fig. 7). Statistically significant 1358 
differences among genotypes are indicated in bold. SO, stratum oriens; SP, stratum 1359 
pyramidale; SR, stratum radiatum; SLM, stratum lacunosum moleculare; ML, molecular 1360 
layer; GCL, granule cell layer; HL, hilus.  1361 
1362 
62 
 
Table 6 Statistical analysis of CD-68 immunoreactivity in young and aged 1363 
mice 1364 
 
Area Source of 
variance 
F value P value 
CA1 - SO Inter F (1, 20) = 2.40 P=0.1369 
Geno F (1, 20) = 2.34 P=0.1417 
Age F (1, 20) = 3.08 P=0.0943 
CA1 - SP Inter F (1, 20) = 2.55 P=0.1259 
Geno F (1, 20) = 2.07 P=0.1652 
Age F (1, 20) = 18.05 P=0.0004 
CA1 - SR Inter F (1, 20) = 1.60 P=0.2206 
Geno F (1, 20) = 1.26 P=0.2756 
Age F (1, 20) = 1.51 P=0.2334 
SLM Inter F (1, 20) = 0.60 P=0.4485 
Geno F (1, 20) = 1.61 P=0.2195 
Age F (1, 20) = 14.00 P=0.0013 
ML Inter F (1, 20) = 1.49 P=0.2362 
Geno F (1, 20) = 2.68 P=0.1174 
Age F (1, 20) = 2.84 P=0.1073 
GCL Inter F (1, 20) = 2.61 P=0.1217 
Geno F (1, 20) = 3.69 P=0.0692 
Age F (1, 20) = 11.83 P=0.0026 
HL Inter F (1, 20) = 0.09 P=0.7701 
Geno F (1, 20) = 0.68 P=0.4192 
Age F (1, 20) = 0.77 P=0.3921 
CA3c Inter F (1, 20) = 1.03 P=0.3229 
Geno F (1, 20) = 2.98 P=0.0995 
Age F (1, 20) = 2.89 P=0.1044 
CA3a,b Inter F (1, 20) = 1.41 P=0.2483 
Geno F (1, 20) = 3.77 P=0.0664 
Age F (1, 20) = 49.70 P<0.0001 
Densitometric analysis of CD68-IR in hippocampal sections from 3- and 9-month-old 1365 
ArcticAβ and wildtype mice (see Fig. 9B). No significant difference was observed in any of 1366 
the regions analysed (2-way ANOVA). SO, stratum oriens; SP, stratum pyramidale; SR, 1367 
stratum radiatum; SLM, stratum lacunosum moleculare; ML, molecular layer; GCL, granule 1368 
cell layer; HL, hilus.  1369 
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